RS53469B - UNITS THAT MODULATE ANDROGEN RECEPTOR - Google Patents

UNITS THAT MODULATE ANDROGEN RECEPTOR

Info

Publication number
RS53469B
RS53469B RS20140420A RSP20140420A RS53469B RS 53469 B RS53469 B RS 53469B RS 20140420 A RS20140420 A RS 20140420A RS P20140420 A RSP20140420 A RS P20140420A RS 53469 B RS53469 B RS 53469B
Authority
RS
Serbia
Prior art keywords
alkyl
hydroxy
hydrogen
alkylamino
amino
Prior art date
Application number
RS20140420A
Other languages
English (en)
Serbian (sr)
Inventor
Gerd Wohlfahrt
Olli Törmäkangas
Harri Salo
Iisa Höglund
Arja Karjalainen
Pia Knuuttila
Patrik Holm
Sirpa Rasku
Anniina Vesalainen
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS53469(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of RS53469B publication Critical patent/RS53469B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RS20140420A 2009-10-27 2010-10-27 UNITS THAT MODULATE ANDROGEN RECEPTOR RS53469B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515909P 2009-10-27 2009-10-27
PCT/FI2010/000065 WO2011051540A1 (en) 2009-10-27 2010-10-27 Androgen receptor modulating compounds

Publications (1)

Publication Number Publication Date
RS53469B true RS53469B (en) 2014-12-31

Family

ID=43383475

Family Applications (3)

Application Number Title Priority Date Filing Date
RS20140420A RS53469B (en) 2009-10-27 2010-10-27 UNITS THAT MODULATE ANDROGEN RECEPTOR
RS20210903A RS62123B1 (sr) 2009-10-27 2010-10-27 Jedinjenja koja moduliraju androgeni receptor
RS20180913A RS57592B1 (sr) 2009-10-27 2010-10-27 Jedinjenja koja moduliraju androgeni receptor

Family Applications After (2)

Application Number Title Priority Date Filing Date
RS20210903A RS62123B1 (sr) 2009-10-27 2010-10-27 Jedinjenja koja moduliraju androgeni receptor
RS20180913A RS57592B1 (sr) 2009-10-27 2010-10-27 Jedinjenja koja moduliraju androgeni receptor

Country Status (36)

Country Link
US (5) US8975254B2 (en.)
EP (5) EP3056485B1 (en.)
JP (1) JP5763083B2 (en.)
KR (2) KR101670299B1 (en.)
CN (2) CN105061313B (en.)
AR (1) AR078793A1 (en.)
AU (1) AU2010311299C1 (en.)
BR (1) BR112012008823B8 (en.)
CA (1) CA2777896C (en.)
CL (1) CL2012000772A1 (en.)
CO (1) CO6531494A2 (en.)
CY (2) CY2020010I2 (en.)
DK (3) DK3056485T3 (en.)
EA (1) EA021170B1 (en.)
ES (3) ES2678073T3 (en.)
GE (1) GEP20166472B (en.)
HK (1) HK1173442A1 (en.)
HR (3) HRP20140919T1 (en.)
HU (2) HUE055528T2 (en.)
IL (2) IL218586A (en.)
LT (3) LT3369732T (en.)
LU (1) LUC00154I2 (en.)
MX (1) MX2012004867A (en.)
MY (1) MY159924A (en.)
NL (1) NL301041I2 (en.)
NO (1) NO2020018I1 (en.)
NZ (1) NZ598747A (en.)
PE (1) PE20121058A1 (en.)
PL (3) PL3056485T3 (en.)
PT (3) PT3056485T (en.)
RS (3) RS53469B (en.)
SI (3) SI2493858T1 (en.)
SM (1) SMT201400138B (en.)
UA (1) UA109535C2 (en.)
WO (1) WO2011051540A1 (en.)
ZA (1) ZA201202655B (en.)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007500A2 (de) * 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2699561B1 (en) 2011-04-21 2015-06-03 Orion Corporation Androgen receptor modulating carboxamides
EP2574607A1 (en) * 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
AU2013202992B2 (en) * 2012-03-15 2015-09-03 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
TW201343644A (zh) * 2012-03-23 2013-11-01 Nihon Nohyaku Co Ltd 噻唑羧醯胺衍生物及其使用方法
SG11201408316SA (en) 2012-06-15 2015-03-30 Taisho Pharmaceutical Co Ltd Branched chain alkyl heteroaromatic ring derivative
WO2014031784A1 (en) 2012-08-23 2014-02-27 Alios Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
CN102952095A (zh) * 2012-10-19 2013-03-06 盛世泰科生物医药技术(苏州)有限公司 一种2-羧酸乙酯-5-溴甲基噻唑的合成方法
EA038819B1 (ru) * 2013-08-21 2021-10-25 Алиос Биофарма, Инк. Противовирусные соединения
WO2015172196A1 (en) * 2014-05-13 2015-11-19 Monash University Heterocyclic compounds and use of same
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
SI3250554T1 (sl) 2015-01-30 2022-09-30 Orion Corporation Derivat karboksiamida in njegovi diastereomeri v stabilni kristalinični obliki
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
SG11201707959VA (en) * 2015-04-09 2017-10-30 Orion Corp Process for the preparation of androgen receptor antagonists and intermediates thereof
CA3024113A1 (en) * 2015-05-18 2016-11-24 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors
EP3388428B1 (en) * 2015-12-07 2021-08-04 Suzhou Sinovent Pharmaceuticals Company Five-membered heterocyclic amides wnt pathway inhibitor
CN107286094A (zh) * 2016-04-12 2017-10-24 常州爱诺新睿医药技术有限公司 一种bay-1841788与药用辅料的固体分散体及其制备方法
LT3495352T (lt) * 2016-08-26 2021-06-10 Bayer Consumer Care Ag Androgeno receptoriaus antagonisto kristalinės formos, paruošimo būdas ir jų panaudojimas
AU2017341723B2 (en) * 2016-10-11 2021-12-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EA201992103A1 (ru) 2017-03-07 2020-01-24 Орион Корпорейшн Получение кристаллического фармацевтического продукта
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
CN116396220A (zh) * 2017-08-09 2023-07-07 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物
CN107602471B (zh) * 2017-09-22 2021-04-27 成都恒汇化成医药科技有限公司 一种达罗鲁胺的晶型制备方法
EP3759076A1 (en) 2018-02-27 2021-01-06 Sandoz AG Crystalline form ii of darolutamide
JP2021535200A (ja) * 2018-08-13 2021-12-16 ナショナル・センター・フォー・バイオロジカル・サイエンス−ティーアイエフアール 治療的介入のためのＨＩＶ−１ Ｎｅｆ−ＣＤ８０／ＣＤ８６相互作用を標的化する阻害剤
US20210386826A1 (en) 2018-11-05 2021-12-16 Pfizer Inc. Combination for Treating Cancer
AU2020215176A1 (en) 2019-01-30 2021-08-05 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020173457A1 (zh) * 2019-02-27 2020-09-03 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
EP3993779A1 (en) 2019-07-02 2022-05-11 Orion Corporation Pharmaceutical composition of darolutamide
CN110590668A (zh) * 2019-07-17 2019-12-20 江苏君若医药有限公司 N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法
AU2020327022A1 (en) 2019-08-08 2022-02-10 Laekna Limited Method of treating cancer
CN111116476A (zh) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 制备抗肿瘤药物多拉米胺的方法
JP2023528200A (ja) 2020-05-11 2023-07-04 オリオン コーポレーション アンドロゲン受容体アンタゴニストおよびその中間体の製造方法
BR112023002295A2 (pt) 2020-08-13 2023-03-14 Pfizer Terapia de combinação
CN111978534B (zh) * 2020-09-07 2022-05-31 陕西师范大学 一种含苯并咪唑液晶基元的侧链型液晶离聚物及其制备方法
WO2022200982A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
CN113527208A (zh) * 2021-08-31 2021-10-22 江西金丰药业有限公司 一步法制备2-氯-4-（1h-吡唑-3-基）苯甲腈的方法
CN113861115A (zh) * 2021-09-10 2021-12-31 浙江师范大学 一种吡唑酰胺类衍生物及合成方法和应用
WO2023161458A1 (en) 2022-02-28 2023-08-31 Química Sintética, S.A. Crystalline form of darolutamide
WO2023194528A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2024074959A1 (en) 2022-10-02 2024-04-11 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2024121163A1 (en) 2022-12-06 2024-06-13 Cancer Research Technology Limited Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
FR2656609B1 (fr) 1989-12-28 1992-03-27 Synthelabo Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
US5578550A (en) 1993-10-08 1996-11-26 American Cyanamid Company Herbicidal oxadiazole carbonamide compounds
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
PL346795A1 (en) 1998-09-22 2002-02-25 Yamanouchi Pharma Co Ltd Cyanophenyl derivatives
BR0213817A (pt) 2001-11-02 2004-10-19 Pfizer Prod Inc Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9
US20050119489A1 (en) * 2001-12-28 2005-06-02 Ladouceur Gaetan H. 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
CA2471754A1 (en) 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Androgen receptor antagonist
US20050119246A1 (en) * 2001-12-28 2005-06-02 Bayer Pharmaceuticals Corporation 1H-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
US20040180889A1 (en) 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
AR040149A1 (es) * 2002-06-07 2005-03-16 Novartis Ag Compuestos de aminoacetonitrilo, un proceso para su preparacion, composicion, y uso del compuesto
WO2004013130A1 (en) * 2002-08-02 2004-02-12 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
DE10322108B4 (de) 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
WO2004111012A1 (ja) 2003-06-12 2004-12-23 Chugai Seiyaku Kabushiki Kaisha イミダゾリジン誘導体
JP4809228B2 (ja) 2003-09-24 2011-11-09 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
WO2006028226A1 (ja) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha 新規イミダゾリジン誘導体およびその用途
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
EP1710237A1 (en) * 2005-04-08 2006-10-11 Bayer CropScience S.A. New heterocyclylethylbenzamide derivatives
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
AR057656A1 (es) * 2005-07-01 2007-12-12 Ligand Pharm Inc Compuestos moduladores de receptores de androgeno y metodods relacionados
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2669736C (en) 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
JP5205274B2 (ja) 2006-11-22 2013-06-05 日本農薬株式会社 新規なピラゾール誘導体、有害生物防除剤及びその使用方法
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
EP2167497A2 (en) 2007-06-29 2010-03-31 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
WO2009028543A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
UY31736A (es) 2008-03-26 2009-11-10 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
CA2725481A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives

Also Published As

Publication number Publication date
HRP20181229T1 (hr) 2018-10-05
KR101670299B1 (ko) 2016-10-28
PL3056485T3 (pl) 2018-12-31
EP3885340A1 (en) 2021-09-29
US20150203479A1 (en) 2015-07-23
GEP20166472B (en) 2016-05-10
CL2012000772A1 (es) 2012-08-24
IL238044A (en) 2016-07-31
MX2012004867A (es) 2012-06-08
ZA201202655B (en) 2012-12-27
EP3369732A1 (en) 2018-09-05
HRP20140919T1 (hr) 2014-11-21
PT3056485T (pt) 2018-07-31
US8975254B2 (en) 2015-03-10
CY2020010I1 (el) 2020-11-25
ES2678073T3 (es) 2018-08-08
SI2493858T1 (sl) 2014-10-30
NL301041I2 (nl) 2020-09-14
CY1124429T1 (el) 2022-07-22
BR112012008823A2 (pt) 2019-02-19
AU2010311299A8 (en) 2012-06-14
CN105061313B (zh) 2017-07-18
SI3056485T1 (en) 2018-08-31
KR101654529B1 (ko) 2016-09-06
LTC2493858I2 (lt) 2022-03-25
SI3369732T1 (sl) 2021-08-31
LUC00154I2 (en.) 2021-02-17
US20200299307A1 (en) 2020-09-24
UA109535C2 (uk) 2015-09-10
US10118933B2 (en) 2018-11-06
WO2011051540A1 (en) 2011-05-05
US9657003B2 (en) 2017-05-23
US20120225867A1 (en) 2012-09-06
CO6531494A2 (es) 2012-09-28
EP3369732B1 (en) 2021-05-26
EP2754656A1 (en) 2014-07-16
WO2011051540A9 (en) 2011-06-23
PL3369732T3 (pl) 2021-12-06
EP2493858A1 (en) 2012-09-05
ES2877248T3 (es) 2021-11-16
EP3056485A1 (en) 2016-08-17
PT2493858E (pt) 2014-09-03
DK3056485T3 (en) 2018-07-30
LT3056485T (lt) 2018-07-25
CY2020010I2 (el) 2020-11-25
JP2013508447A (ja) 2013-03-07
IL218586A (en) 2015-10-29
US10711013B2 (en) 2020-07-14
RS57592B1 (sr) 2018-11-30
HUE039390T2 (hu) 2018-12-28
AU2010311299B2 (en) 2014-07-17
LTPA2020514I1 (lt) 2020-07-27
CN105061313A (zh) 2015-11-18
US20170260206A1 (en) 2017-09-14
NO2020018I1 (no) 2020-06-17
JP5763083B2 (ja) 2015-08-12
AU2010311299C1 (en) 2023-02-02
US11046713B2 (en) 2021-06-29
WO2011051540A8 (en) 2012-04-19
ES2486263T3 (es) 2014-08-18
AR078793A1 (es) 2011-12-07
CA2777896A1 (en) 2011-05-05
DK2493858T3 (da) 2014-09-08
BR112012008823B1 (pt) 2021-01-12
AU2010311299A1 (en) 2012-04-12
DK3369732T3 (da) 2021-07-26
SMT201400138B (it) 2014-11-10
NZ598747A (en) 2013-06-28
EA021170B1 (ru) 2015-04-30
EP3056485B1 (en) 2018-05-09
CA2777896C (en) 2017-05-23
LUC00154I1 (en.) 2020-05-19
KR20120102057A (ko) 2012-09-17
HRP20211180T1 (hr) 2021-10-15
HK1173442A1 (zh) 2013-05-16
EA201270597A1 (ru) 2012-10-30
IL218586A0 (en) 2012-05-31
PE20121058A1 (es) 2012-08-18
BR112012008823B8 (pt) 2021-05-25
PT3369732T (pt) 2021-07-06
HUE055528T2 (hu) 2021-12-28
CN102596910B (zh) 2015-11-25
CN102596910A (zh) 2012-07-18
US20190100536A1 (en) 2019-04-04
KR20160105927A (ko) 2016-09-07
RS62123B1 (sr) 2021-08-31
EP2493858B1 (en) 2014-07-02
LT3369732T (lt) 2021-06-25
MY159924A (en) 2017-02-15
PL2493858T3 (pl) 2015-01-30

Similar Documents

Publication Publication Date Title
RS53469B (en) UNITS THAT MODULATE ANDROGEN RECEPTOR
RS52812B (en) PYROLIDIN-2-DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS
RS54790B1 (sr) Trisupstituisani heterocikli kao inhibitori replikacije virusa hepatitisa c hcv
RS52307B (en) CONDENSED CYCLIC UNITS
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
RS51970B (en) TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS
PE20130155A1 (es) Derivados de ariletinilo
RS52661B (en) THERAPEUTIC MEANS
HRP20070510T3 (en) Benzimidazole derivative and its use as a ii receptor antagonist
PE20160682A1 (es) Composiciones y metodos para modular los receptores x farnesoides
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
RS53389B (en) PHARMACEUTICAL UNITS
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
PE20140961A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
CY1120477T1 (el) Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων
AR048669A1 (es) Derivados biciclicos de bisamida
RS53705B1 (en) DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS
RS53038B (en) OXADIAZOLA DERIVATIVE Activate Sphingosine-1-Phosphate (SIP)
RS54355B1 (en) Isoxazole-pyridine derivatives
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
RS52562B (en) (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
RS52261B (en) AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3